U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Sterling USA Nutraceuticals Lab, LLC - 02/24/2017
  1. Warning Letters

CLOSEOUT LETTER

Sterling USA Nutraceuticals Lab, LLC

Recipient:
Sterling USA Nutraceuticals Lab, LLC

United States

Issuing Office:

United States

 

  

Black HHS-Blue FDA Logo

 

 

 
Los Angeles District
19701 Fairchild Road
Los Angeles, CA 92612 

February 24, 2017

Mr. Fahim Rahman
Marketing Director and Co-Owner
Sterling USA Nutraceuticals Lab, LLC
6739 San Fernando Rd.
Glendale, CA 91201-1704

Dear Mr. Rahman:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter, WL 06-13, dated November 16, 2012. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve the firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects the firm to maintain compliance and will continue to monitor their state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

CDR Steven E. Porter, Jr.
Los Angeles District Director

Back to Top